Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 3/20 | 0.40 |
| ▸ | ARF6 | P62330 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275273 | 0.92 | PLAT (0.40) | PLATARF6PDE2APGRNR3C2 | |
| SCHEMBL10313534 | 0.90 | PGR (0.38) | PLATARF6PGRNR3C2PDE3B | |
| SCHEMBL10276317 | 0.88 | ALDH1A1 (0.44) | PLATARF6KDM4E | |
| SCHEMBL10275704 | 0.85 | PDE2A (0.43) | PLATPDE2ASLC11A2PDE5A | |
| SCHEMBL10276685 | 0.84 | HSD11B1 (0.40) | PLATARF6PGRNR3C2PDE3B | |
| SCHEMBL10313546 | 0.83 | ARF6 (0.41) | PLATARF6PDE2APGRNR3C2 | |
| SCHEMBL10275482 | 0.83 | PLAT (0.40) | PLATARF6PDE2APGRNR3C2 | |
| SCHEMBL10275393 | 0.83 | ARF6 (0.35) | PLATARF6PDE2AAPPPDE5A | |
| SCHEMBL10276495 | 0.82 | ALDH1A1 (0.44) | PLATKDM4E | |
| SCHEMBL10275276 | 0.82 | HSD11B1 (0.40) | PLATARF6PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PLAT 2180/4885ARF6 3355/4885PDE2A 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.